Non-interventional, open-label, single group, multicentric post-marketing surveillance to
monitor the safety and effectiveness of TYKERB® tablets administered in Korean patients
according to the prescribing information TYKERB® is a registered trademark of the
GlaxoSmithKline group of companies.